Navigation Links
Molecular Devices, LLC Introduces SoftMax Pro® 6 Microplate Data Acquisition and Analysis Software With Powerful New Data Analysis and Reporting Features
Date:10/27/2011

SUNNYVALE, Calif., Oct. 27, 2011 /PRNewswire/ -- Today, Molecular Devices, LLC, a leader in bioanalytical systems for drug discovery, life science research, and bioassay/test development, today announced the launch of SoftMax® Pro 6 Microplate Data and Analysis Software. SoftMax Pro software is the industry standard with superior data analysis capabilities critical to researchers in R&D, drug manufacturing, quality control, and analysis in the biotech and pharmaceutical industries.

(Logo:  http://photos.prnewswire.com/prnh/20100406/SF82092LOGO)

SoftMax Pro is a robust, all-in-one software package. With the new data analysis features such as 3-D graphing, plate cloning, side-by-side comparison view, and Syntax Helper, it's easy to do all your data analysis without the need to export your data. Additionally, the new all-inclusive reporting removes the need to copy and paste your graphs or tables into text formatted documents. These new features help eliminate the need for additional software.

Commenting on the launch of SoftMax Pro 6 software, Mikey Kindler, BioResearch Director, Molecular Devices, noted, "The release of SoftMax® Pro 6 Data Acquisition and Analysis Software demonstrates our commitment to world-class software development. Not only did we redesign the user interface with significantly expanded data analysis features, but also this new platform is designed with expansion in mind, allowing us to quickly address future user needs and market requirements."

Since its introduction, SoftMax Pro software has set the standard for data acquisition and analysis in the microplate reader industry paired with the award-winning microplate reader offering. SoftMax Pro® 6 Software works with Molecular Devices' SpectraMax® absorbance readers, Gemini™ XPS and EM fluorescence readers, SpectraMax Paradigm® platform, M-series, and FilterMax Series microplate readers.

Designed exclusively for the unique requirements and preferences of microplate instrumentation, SoftMax Pro 6 software offers a clean interface with easy access to the most common tasks based on Microsoft's ribbon interface. SoftMax Pro 6 software expands the data analysis features even further with new Syntax Helper, additional curve fits, 3-D graphing, side-by-side data comparison, and plate cloning. SoftMax Pro 6 also enhances the customization tools with all-inclusive reporting containing live mini-graphs and tables, image display, and layout flexibility. The new SoftMax Pro 6 requires minimal training for everyone in your lab and will maximize your productivity with the expanded feature offering.

About Molecular Devices, LLC

At Molecular Devices we have one focus—our customers. Whether a long-time user, recent adopter, or prospective customer, your needs fuel our actions. We hire creative, best-in-class people to design, manufacture, and commercialize analytical instruments, software, and assays as well as provide dedicated follow-on support. Understanding your laboratory workflow is our top priority, and we direct product development toward solving your unique issues. Our instruments offer a full spectrum of detection technologies and meet all throughput needs—from dedicated, single-readout devices to multi-readout systems. Our goal is to deliver highly relevant analytical products to detect biology, decode data, and drive discovery. With headquarters in Silicon Valley and offices around the globe, we support and enrich efforts of the international BioResearch, BioPharma, and BioTesting communities. Visit us today at www.MolecularDevices.com.

Molecular Devices products are for Research Use Only. Not for use in diagnostic procedures.

The trademarks mentioned herein are the property of Molecular Devices, LLC, or their respective owners.

© 2011. Molecular Devices, LLC


'/>"/>
SOURCE Molecular Devices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
2. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
4. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
5. Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
8. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
9. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
10. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
11. Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 2016 Research and Markets has announced the addition ... to 2021" report to their offering. ... , , The global spinal ... 2021, at a CAGR of 5.3% from 2016 to 2021. Factors such ... cases, increasing government spending on healthcare, and rising income levels are propelling ...
(Date:12/5/2016)... , December 5, 2016 ... to Deputy Chairman   ... selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative and ... been appointed as non-executive Chairman, effective January 1 st ... Mission Therapeutics as a non-executive Director in July 2015. ...
(Date:12/4/2016)... Attorney General of Louisiana , Charles ... firm of Kahn Swick & Foti, LLC ("KSF"), announces that ... LCI ). On November 3, ... in Generic-Drug Probe to Be Filed by Year-End," which reported ... two years ago, now spans more than a dozen companies," ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... 2016 , ... Researchers at Johns Hopkins All Children’s Hospital want to learn ... the course of three years, researchers will study concussions and changes in brain function ... with special sensors, will track the location and force of the hit. The sensors ...
(Date:12/5/2016)... ... 05, 2016 , ... “Epilepsy Awareness,” which can be found ... a conversation about epilepsy, bearing down on the social stigma and lack of ... with epilepsy within their lifetime. With such a large percentage of people affected, ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... Keynote speaker for the 21st Annual International Congress on Hematologic Malignancies®: Focus on ... PER® president, Phil Talamo said, “We are honored to have Amy E. Herman ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... geographic lines. The goal of Castlewood Treatment Centers has always been to promote ... to as many people as possible. In that spirit, Castlewood has announced two ...
(Date:12/5/2016)... , ... December 05, 2016 , ... Dr. Barry M. ... Cosmetic Plastic Surgery, who recently participated in the 36th Annual Cutting Edge Aesthetic Symposium ... the newest techniques for getting that perfect, yet natural-looking, nose. Dr. Weintraub, who is ...
Breaking Medicine News(10 mins):